中国临床药理学杂志

德谷胰岛素利拉鲁肽联合二甲双胍治疗胰岛素及口服降糖药控制不佳2型糖尿病患者的临床研究

PDF下载

金佳妮 ¹ , 武红梅 ^2a , 王斌 ^2b , 何圣清 ^2a , 龙爱梅 ^2a , 潘霞明 ^2a , 孟莞瑞 ^2a , 邓丽萍 ^2a

中国临床药理学杂志 | 临床与基础桥接研究 2025,41(21): 3014-3018

收起

中国临床药理学杂志 |临床与基础桥接研究 2025 , 41 (21) : 3014 -3018

德谷胰岛素利拉鲁肽联合二甲双胍治疗胰岛素及口服降糖药控制不佳2型糖尿病患者的临床研究

全屏

金佳妮¹, 武红梅^2a, 王斌^2b, 何圣清^2a, 龙爱梅^2a, 潘霞明^2a, 孟莞瑞^2a, 邓丽萍^2a

作者信息

^1.广州中医药大学深圳临床医学院，广东深圳 518116

^2a.深圳市龙岗中心医院，内分泌科，广东深圳 518116

^2b.深圳市龙岗中心医院，营养科，广东深圳 518116

通讯作者:

武红梅，主任医师 MP: 15986804869 E-mail: wuhongmei-62@163.com

作者简介:

金佳妮（1998-），女，硕士研究生，主要从事内分泌代谢疾病的相关研究

Clinical trial of insulin degludec and liraglutide combination with metformin in the treatment of type 2 diabetes mellitus patients with poorly controlled insulin and oral hypoglycemic drugs

Jia-ni JIN¹, Hong-mei WU^2a, Bin WANG^2b, Sheng-qing HE^2a, Ai-mei LONG^2a, Xia-ming PAN^2a, Wan-rui MENG^2a, Li-ping DENG^2a

Affiliations

^1.Shenzhen Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen 518116, Guangdong Province, China

^2a.Department of Endocrinology, Longgang Central Hospital, Shenzhen 518116, Guangdong Province, China

^2b.Department of Nutrition, Longgang Central Hospital, Shenzhen 518116, Guangdong Province, China

出版时间: 2025-11-17 doi: 10.13699/j.cnki.1001-6821.2025.21.003

文章导航

摘要

收起

目的

观察德谷胰岛素利拉鲁肽注射液联合二甲双胍片治疗胰岛素及口服降糖药控制不佳2型糖尿病（T2DM）患者的临床疗效及安全性。

方法

将胰岛素及口服降糖药控制不佳T2DM患者按照队列法分为对照组和试验组。2组患者均接受二甲双胍片进行基础治疗，在此基础上，对照组给予每日多次预混门冬胰岛素30注射液治疗，起始注射剂量为0.2~0.4 U·kg^-1·d^-1，每日2次注射，根据血糖水平调整，每3~5 d调整1次，每次增减1~4 U；试验组予以德谷胰岛素利拉鲁肽注射液治疗，起始注射10~16剂量单位，每日1次皮下注射，每1~2周根据血糖水平调整剂量，每次增减2~4剂量单位。2组患者均治疗3个月。比较2组患者的临床疗效、血糖水平、血脂代谢水平、胰岛功能，并进行安全性评价。

结果

试验组入组40例，对照组入组40例。治疗后，试验组和对照组的总有效率分别为97.50%（39例/40例）和80.00%（32例/40例），在统计学上差异有统计学意义（P<0.05）。治疗后，试验组和对照组的糖化血红蛋白水平分别为（6.14±1.03）%和（7.20±1.08）%，空腹血糖水平分别为（6.25±1.34）和（7.82±1.26）mmol·L^-1，餐后2 h血糖水平分别为（6.37±0.64）和（7.15±0.67）mmol·L^-1，三酰甘油水平分别为（1.87±0.62）和（2.64±0.79）mmol·L^-1，血清总胆固醇水平分别为（4.53±0.62）和（5.18±0.76）mmol·L^-1，空腹胰岛素水平分别为（7.16±0.71）和（8.56±0.94）μU·mL^-1，胰岛β细胞功能指数水平分别为（58.36±5.87）%和（50.72±6.14）%，胰岛素抵抗指数水平分别为1.52±0.44和2.09±0.47，试验组的上述指标与对照组比较，在统计学上差异均有统计学意义（均P<0.05）。试验组的药物不良反应主要有胃肠道反应、头晕、心率升高和低血糖，对照组的药物不良反应主要有胃肠道反应、头晕和低血糖。试验组和对照组的总药物不良反应发生率分别为15.00%和12.50%，在统计学上差异无统计学意义（P>0.05）。

结论

德谷胰岛素利拉鲁肽注射液联合二甲双胍片治疗胰岛素及口服降糖药控制不佳T2DM患者的临床疗效显著，其能有效控制患者的血糖和血脂代谢水平，改善胰岛功能，且安全性较好。

关键词

德谷胰岛素利拉鲁肽注射液 / 二甲双胍片 / 2型糖尿病 / 血糖 / 安全性评价

Abstract

收起

Objective

To observe the clinical efficacy and safety of insulin degludec and liraglutide combination with metformin tablets in the treatment of type 2 diabetes mellitus (T2DM) patients with poorly controlled insulin and oral hypoglycemic drugs.

Methods

The T2DM patients with poor control of insulin and oral hypoglycemic drugs were randomly divided into control group and treatment group according to the queue method. Both groups of patients received metformin tablets for basic treatment. On this basis, the control group was given premixed insulin aspartic 30 injection multiple times a day for treatment. The initial injection dose was 0.2-0.4 U·kg^-1·d^-1, twice a day, adjusted according to the blood glucose level, once every 3-5 days, with an increase or decrease of 1-4 U each time. The treatment group was treated with insulin degludec and liraglutide injection. The initial injection was 10 to 16 dose units, administered subcutaneously once a day. The dose was adjusted every 1 to 2 weeks based on the blood glucose level, with an increase or decrease of 2 to 4 dose units each time. Both groups of patients were treated for 3 months. The clinical efficacy, blood glucose level, lipid metabolism level, pancreatic islet function and safety of the two groups of patients were compared.

Results

A total of 40 cases in the control group and 40 cases in the treatment group were enrolled. After treatment, the total effective rates of the treatment group and the control group were 97.50% (39 cases/40 cases) and 80.00% (32 cases/40 cases), the difference was statistically significant (P<0.05). After 3 months of treatment, the glycosylated hemoglobin levels of the treatment group and the control group were (6.14±1.03)% and (7.20±1.08)%, respectively; the fasting blood glucose levels were (6.25±1.34) and (7.82±1.26) mmol·L^-1, respectively; the 2 h postprandial blood glucose levels were (6.37±0.64) and (7.15±0.67) mmol·L^-1, respectively; the triglyceride levels were (1.87±0.62) and (2.64±0.79) mmol·L^-1, respectively; the serum total cholesterol levels were (4.53±0.62) and (5.18±0.76) mmol·L^-1, respectively; and the fasting insulin levels were (7.16±0.71) and (8.56±0.94) μmol·L^-1, respectively; islet β cell function index levels were (58.36±5.87)% and (50.72±6.14)%, respectively; while insulin resistance index levels were 1.52±0.44 and 2.09±0.47, respectively, the differences were statistically significant between the two groups (all P<0.05). The main adverse drug reactions in the treatment group were gastrointestinal reactions, dizziness, increased heart rate and hypoglycemia, while those in the control group were mainly gastrointestinal reactions, dizziness and hypoglycemia. The total incidences of adverse drug reactions in the treatment group and the control group were 15.00% and 12.50%, respectively, and there was no statistically significant difference (P>0.05).

Conclusion

Insulin degludec and liraglutide injection has shown significant clinical efficacy in the treatment of T2DM with poor control of insulin and oral hypoglycemic drugs. It can effectively control patients’ blood glucose and lipid metabolism levels, improve pancreatic function, and has good safety.

Key words

insulin degludec and liraglutide injection / metformin tablet / type 2 diabetes mellitus / blood glucose / safety

引用本文

金佳妮, 武红梅, 王斌, 何圣清, 龙爱梅, 潘霞明, 孟莞瑞, 邓丽萍. 德谷胰岛素利拉鲁肽联合二甲双胍治疗胰岛素及口服降糖药控制不佳2型糖尿病患者的临床研究. 中国临床药理学杂志, 2025 , 41 (21) : 3014 -3018 . DOI: 10.13699/j.cnki.1001-6821.2025.21.003

Jia-ni JIN, Hong-mei WU, Bin WANG, Sheng-qing HE, Ai-mei LONG, Xia-ming PAN, Wan-rui MENG, Li-ping DENG. Clinical trial of insulin degludec and liraglutide combination with metformin in the treatment of type 2 diabetes mellitus patients with poorly controlled insulin and oral hypoglycemic drugs[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (21) : 3014 -3018 . DOI: 10.13699/j.cnki.1001-6821.2025.21.003

基金

收起

广东省医学科研基金资助项目(A2024404)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

2025年第41卷第21期

PDF下载

532

422

引用本文

BibTeX

文章信息

doi: 10.13699/j.cnki.1001-6821.2025.21.003

接收时间：2025-05-10
首发时间：2026-08-05
出版时间：2025-11-17

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-05-10

基金

广东省医学科研基金资助项目(A2024404)

作者信息

^1.广州中医药大学深圳临床医学院，广东深圳 518116

^2a.深圳市龙岗中心医院，内分泌科，广东深圳 518116

^2b.深圳市龙岗中心医院，营养科，广东深圳 518116

通讯作者:

武红梅，主任医师 MP: 15986804869 E-mail: wuhongmei-62@163.com

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/10.13699/j.cnki.1001-6821.2025.21.003

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT